Is Neuphoria Therapeutics Inc. (NEUP) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 54.1% / 30% | 0.5% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 1.2% / 33% | 54.1% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 1.0% / 33% | 45.6% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 54.1% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 1.0% / 33% | 45.6% / 33% | 0.5% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -12.4% | |
| Net Margin | -37.8% | |
| Return on Equity (ROE) | -26.1% | |
| Return on Assets (ROA) | -4.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$15M |
| Free Cash Flow | -$15M |
| Total Debt | $272,738 |
| Debt-to-Equity | 0.1 |
| Current Ratio | 9.0 |
| Total Assets | $28M |
Price & Trading
| Last Close | $4.20 |
| 50-Day MA | $4.27 |
| 200-Day MA | $6.93 |
| Avg Volume | 49K |
|
52-Week Range
$3.65
| |
About Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Neuphoria Therapeutics Inc. (NEUP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Neuphoria Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Neuphoria Therapeutics Inc.'s debt ratio?
Neuphoria Therapeutics Inc.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.0%.
What are Neuphoria Therapeutics Inc.'s key financial metrics?
Neuphoria Therapeutics Inc. has a market capitalization of $22M. The company maintains a gross margin of 100.0% and a net margin of -37.8%. Return on equity stands at -26.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.